In hepatocellular carcinoma cells (HepG2), ferroptosis inducers (sulfasalazine, sorafenib, and erastin) activated ferritinophagy and increased cellular Fe2+ levels, consequently activating AMPK phosphorylation and suppressing nuclear translocation of SREBP1, then inhibiting BCAT2 transcription (28). This evidence concerns the gene BCAT2 and hepatocellular carcinoma.